Pinealon
Also known as: EDR, EDR peptide, Glu-Asp-Arg, T-33 peptide
5 notable studies · 5 references
TLDR
Pinealon is the synthetic tripeptide Glu-Asp-Arg (EDR), with direct cell and animal evidence for effects on oxidative stress, neuronal survival, gene regulation, and neuroplasticity, but its evidence base remains heavily concentrated within one research network and controlled human evidence for cognition, sleep, neurodegenerative disease, or anti-aging effects is insufficient.
Research Supports
- Studied for effects on oxidative stress and reactive-oxygen-species accumulation in cell models
- Investigated for neuroprotective activity across models of hypoxia and neurodegeneration
- Studied in Alzheimer's-disease mouse models for neuroplasticity-related effects
- Investigated for possible gene-regulatory/nuclear interactions
- Associated with early, low-certainty human observations on memory and aging
Observations Reported in Research
- Reduced reactive oxygen species and necrotic cell death in cerebellar granule cells, neutrophils, and PC12 cells under oxidative stress (Khavinson et al., 2011)
- Fluorescently labeled EDR peptide localized to the cytoplasm, nucleus, and nucleolus of HeLa cells, with sequence-dependent DNA interactions reported (Fedoreyeva et al., 2011)
- Reported protective neurobehavioral effects in rat offspring exposed to prenatal hyperhomocysteinemia (Arutjunyan et al., 2012)
- EDR and KED showed neuroplasticity-related effects, including on dendritic spines, in a 5xFAD Alzheimer's mouse model (Khavinson et al., 2021)
- No modern randomized human trial establishing cognitive, sleep, or anti-aging benefit was identified
These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.
At a Glance
Classification: Synthetic tripeptide; short peptide bioregulator; experimental neuroprotective peptide
Pinealon is the synthetic three-amino-acid peptide Glu-Asp-Arg (EDR). It belongs to the Khavinson short-peptide-bioregulator research program and has primarily been investigated in relation to oxidative stress, neuronal survival, cognitive function, hypoxic brain injury, neuroplasticity, cellular aging, gene regulation, and Alzheimer's-disease models. Direct experiments show Pinealon can reduce reactive-oxygen-species accumulation and cell death in experimental cell systems. Animal research has produced neuroprotective and behavioral signals. The evidence has an important limitation: most of the literature comes from the same interconnected Khavinson/St. Petersburg research network, while rigorous independent human evidence remains extremely limited.
What Is Pinealon?
Pinealon is an unusually small peptide: Glu-Asp-Arg (EDR) — just three amino acids. Unlike Adamax, its chemical identity is well defined. Pinealon should not automatically be described as a pineal-gland peptide. The EDR literature focuses heavily on neuronal and cerebral-cortex biology, and some sources associate it with Cortexin-related research. The “Pinealon” name itself shouldn't be used as evidence that the pineal gland is its specific physiological target. Pinealon is also distinct from Epitalon (AEDG), the tetrapeptide much more strongly associated with the pineal/gerontology research program.
What Are Researchers Studying?
Oxidative stress
This is one of Pinealon's clearest direct experimental effects. In a 2011 study, EDR reduced reactive oxygen species accumulation in cerebellar granule cells, neutrophils, and PC12 cells under experimentally induced oxidative stress. It also reduced necrotic cell death and altered ERK1/2 activation and cell-cycle behavior. That's legitimate biological activity. It does not establish Pinealon as a general-purpose antioxidant therapy in humans.
Neuroprotection
EDR has been studied across experimental models involving oxidative stress, hypoxia, neurodegeneration, prenatal hyperhomocysteinemia, and Alzheimer's-like pathology. The evidence suggests potential neuroprotective activity in cells and animals. A 2020 review summarizes effects involving apoptosis, antioxidant systems, and neuronal function. Human therapeutic neuroprotection remains unestablished.
Cognition and memory
Animal studies have reported effects on learning and behavioral measures after neurological/metabolic stress. Pinealon has also been associated with claims of improved memory in elderly people in publications from the originating research network. The 2020 EDR review cites such observations. This human evidence is nowhere near the standard of a modern, independently replicated randomized cognitive trial. Human claims/observations exist; human cognitive efficacy is not established.
Alzheimer's-disease biology
EDR has been studied in models related to Alzheimer's disease. Research has examined dendritic spines, amyloid-associated neuronal injury, apoptosis-related proteins, antioxidant enzymes, and gene expression. A 2021 study using 5xFAD mice, a transgenic Alzheimer's model, investigated EDR and KED and reported neuroplasticity-related effects. This is Alzheimer's model research. It does not establish prevention or treatment of Alzheimer's disease in humans.
Gene regulation
This is one of the more unusual parts of Pinealon biology. A 2011 experiment used fluorescently labeled short peptides and found peptide-associated fluorescence within the cytoplasm, nucleus, and nucleolus of HeLa cells. The investigators also reported sequence-dependent interactions between Pinealon and nucleic-acid structures in vitro. This supports investigating direct gene-regulatory mechanisms. It does not prove the simplified claim that Pinealon binds DNA and switches on anti-aging genes in humans.
Cellular aging
Pinealon is frequently discussed as an “anti-aging peptide.” The actual research is more modest. Investigators have studied oxidative damage, cell survival, gene expression, neurodegeneration-associated processes, and age-associated neuronal changes. Those are legitimate aging-related research areas. There is no controlled evidence demonstrating that Pinealon slows human biological aging, extends human lifespan, prevents dementia, or reverses brain aging.
Sleep and circadian biology
Pinealon has recently attracted attention online for possible effects on sleep and REM sleep. This is currently far ahead of the published evidence. Recent coverage acknowledges that the human safety/effectiveness literature remains sparse and that much of the enthusiasm comes from anecdote or extrapolation rather than controlled sleep trials. Improved REM sleep should not be listed as an established research finding.
How Does It Work?
The mechanism isn't settled. Experimental findings support several possibilities: EDR enters the cell and nucleus and may interact with nucleic-acid or chromatin-associated systems, with changes in gene expression and in antioxidant enzymes, apoptosis-related proteins, ERK signaling, and neuronal function. Fluorescence experiments demonstrated nuclear localization of labeled short peptides, while in-vitro assays reported sequence-dependent interactions with DNA structures. Other research implicates proteins/pathways including SOD2, GPX1, Caspase-3, p53, PPAR signaling, and MAPK/ERK. A single primary receptor comparable to GLP-1R or GHSR has not been established.
What Does the Research Show?
Human research
Very limited and low-certainty. The literature contains reports and reviews describing human observations involving memory, psychoemotional measures and aging-associated outcomes. The evidence is characterized by small studies, older/regional literature, limited methodological detail, investigator concentration, and little independent replication. There is no modern large randomized trial establishing Pinealon for cognitive impairment, Alzheimer's disease, dementia, sleep disorders, depression, or longevity. Human evidence maturity: LOW / UNCERTAIN.
Animal research
Considerably stronger than the human evidence. Pinealon/EDR has been investigated in rats, hypoxia models, prenatal hyperhomocysteinemia, neurodegeneration models, and 5xFAD Alzheimer's-model mice. The studies support biological activity and provide hypotheses worth testing clinically. They do not establish human therapeutic efficacy.
In-vitro research
This is Pinealon's strongest evidence category. Direct experiments demonstrate effects involving reactive oxygen species, cell survival, ERK1/2 signaling, cell-cycle regulation, nuclear localization, DNA interaction, and neuronal morphology. The 2011 oxidative-stress paper is particularly useful because it directly identifies Pinealon/EDR rather than relying on a broader peptide extract.
Notable Studies
Pinealon Increases Cell Viability by Suppression of Free Radical Levels and Activating Proliferative Processes
in-vitroResearchers exposed several cellular systems to oxidative stress and examined Pinealon/EDR. Pinealon reduced reactive oxygen species accumulation in cerebellar granule cells, neutrophils, and PC12 cells, reduced necrotic cell death, delayed ERK1/2 activation, and modified cell-cycle behavior.
Limitations: Cellular experiments do not establish clinical neuroprotection, cognitive improvement, or anti-aging effects in humans. The authors proposal of direct genomic interaction goes beyond what the functional outcomes alone prove.
View publication →Penetration of Short Fluorescence-Labeled Peptides Into the Nucleus in HeLa Cells and In Vitro Specific Interaction of the Peptides With Deoxyribooligonucleotides and DNA
in-vitroFluorescently labeled Pinealon and other short peptides were examined in HeLa cells. Fluorescence was detected in the cytoplasm, nucleus, and nucleolus. The researchers also reported sequence-dependent interactions between the peptides and nucleic-acid structures in vitro, including differential interactions with particular DNA sequences.
Limitations: Fluorescent labeling can alter molecular behavior, and in-vitro peptide-DNA interaction does not establish clinically meaningful gene regulation in humans.
View publication →Pinealon Protects the Rat Offspring From Prenatal Hyperhomocysteinemia
animalResearchers investigated Pinealon in offspring exposed to prenatal hyperhomocysteinemia, an experimental condition capable of disrupting nervous-system development and behavior. The study reported protective effects involving neurobehavioral outcomes, supporting investigation of EDR as a neuroprotective peptide. The paper is part of the direct Pinealon preclinical literature.
Limitations: Specific rodent developmental model with uncertain translation to human cognitive aging or neurological disease.
View publication →EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease
in-vitroThe authors reviewed experimental EDR findings involving neuronal function, apoptosis, antioxidant systems, gene expression, and Alzheimer's-related pathways. They proposed mechanisms involving nuclear interactions and changes in MAPK/ERK, caspase-3, p53, SOD2, GPX1, and transcription-associated pathways.
Limitations: Review rather than a new controlled experiment, written by investigators from the same research network responsible for much of the underlying EDR literature.
View publication →Neuroprotective Effects of Tripeptides—Epigenetic Regulators in Mouse Model of Alzheimer's Disease
animalResearchers studied EDR and KED in a transgenic mouse model of Alzheimer's disease and examined neuroplasticity-associated endpoints, including dendritic spines. The results supported potential neuroprotective effects of the short peptides in the experimental model.
Limitations: Mouse Alzheimer's model rather than human disease; more than one peptide was investigated; mechanistic modeling should not be confused with demonstrated therapeutic action. The publication has also had a later figure correction, although the authors reported that the conclusions were unchanged.
View publication →What We Still Don't Know
Human pharmacokinetics. Human bioavailability. Whether meaningful concentrations reach the human brain. Primary molecular target. Whether proposed DNA interactions occur meaningfully in vivo. Whether it improves memory in rigorous randomized human trials. Whether it changes sleep architecture. Whether it prevents cognitive decline. Whether it modifies Alzheimer's disease. Whether it affects dementia risk. Whether it slows biological aging. Long-term safety. Drug interactions. Reproductive safety. Dose-response relationships in humans. Whether the findings replicate outside the originating research network. Whether research-market material consistently matches experimentally studied EDR.
Related Compounds
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the Pinealon research with you.
Get the Aminodex Pinealon Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
- Khavinson V, Ribakova Y, Kulebiakin K, et al. Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes. Rejuvenation Research. 2011;14(5):535–541. https://pubmed.ncbi.nlm.nih.gov/21978084/
- Khavinson V, Linkova N, Kozhevnikova E, Trofimova S. EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease. Molecules. 2020;26(1):159.
- Khavinson V, Ilina A, Kraskovskaya N, et al. Neuroprotective Effects of Tripeptides—Epigenetic Regulators in Mouse Model of Alzheimer's Disease. Pharmaceuticals. 2021;14(6):515.
- Arutjunyan A, et al. Pinealon protects the rat offspring from prenatal hyperhomocysteinemia. International Journal of Clinical and Experimental Medicine. 2012.
- Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow). 2011;76(11):1210–1219.
Supplier Listings
A directory of relevant research suppliers for this compound is not yet available.